Pelizaeus-Merzbacher disease Neurology/Pediatrics
Conditions
Interventions
Low dose curcumin (1mg/kg/day, oral, once a day) for 2 months followed by high dose curcumin (4mg/kg/day, oral, once a day) for 10 months.
Sponsors
Inoue Ken
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Patients with genetically confir med Pelizaeus-Merzbacher disease
Exclusion criteria
Exclusion criteria: 1) Individuals who have other s erious medical problems that is not associated with PMD including hepatic, renal or other dysfunctions. 2) Individuals who cannot orally intake medication (those using tube feeding are acceptable). 3)Individuals who is currently taking anti-coagulants. 4) Individuals who is regularly t aking theracurumin or other curcumin-containing products.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in clinical evaluat ion scores (PMD-FDS, GMFM) after 12 months treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in the myelinatio n in the brain by T2 and T1 we ighted images (including FAIR) by MRI examination. Shortening of latency by audit ory brainstem response exami nation. Improvement in general health condition including increase of body weight. | — |
Contacts
Public ContactKen Inoue
National Center of Neurology and Psychiatry
Outcome results
None listed